SCLX:NSD-Scilex Holding Company (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 0.9001

Change

+0.10 (+12.51)%

Market Cap

N/A

Volume

1.40M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

+0.64 (+0.83%)

USD 240.42B
AMGN Amgen Inc

+6.24 (+1.99%)

USD 168.11B
SNY Sanofi ADR

+0.35 (+0.62%)

USD 144.83B
GILD Gilead Sciences Inc

+0.83 (+1.01%)

USD 104.50B
BIIB Biogen Inc

+4.53 (+2.40%)

USD 29.04B
GRFS Grifols SA ADR

+0.13 (+1.50%)

USD 6.96B
AMRN Amarin Corporation PLC

+0.02 (+2.87%)

USD 0.23B
MIRA MIRA Pharmaceuticals, Inc. Com..

-0.03 (-2.73%)

USD 0.02B
SCLXW Scilex Holding Company

-0.04 (-13.97%)

N/A

ETFs Containing SCLX

BTEC 0.00 % 0.42 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -55.88% 10% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -55.88% 10% F 14% F
Trailing 12 Months  
Capital Gain -39.18% 30% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.18% 30% F 22% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -34.11% 20% F 8% B-
Dividend Return -34.11% 20% F 8% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 37.78% 30% F 49% F
Risk Adjusted Return -90.27% 10% F 8% B-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector